scispace - formally typeset
S

Suhendan Ekmekcioglu

Researcher at University of Texas MD Anderson Cancer Center

Publications -  91
Citations -  8587

Suhendan Ekmekcioglu is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Melanoma & Immunotherapy. The author has an hindex of 36, co-authored 82 publications receiving 7212 citations. Previous affiliations of Suhendan Ekmekcioglu include University of Texas at Austin & Istanbul University.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

The Protein Product of the Tumor Suppressor Gene, Melanoma Differentiation-Associated Gene 7, Exhibits Immunostimulatory Activity and Is Designated IL-24

Eva G. Caudell, +9 more
- 15 Jun 2002 - 
TL;DR: The melanoma differentiation-associated gene 7 (mda-7) has been studied primarily in the context of its tumor suppressor activity and has the expression profile and major functional attributes that justify its designation as an IL, because human blood leukocytes can be stimulated to produce MDA-7/IL-24.
Journal ArticleDOI

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Jahan Khalili, +20 more
- 01 Oct 2012 - 
TL;DR: A novel mechanism of immune suppression sensitive to BRAF(V600E) inhibition is revealed, and indicates that clinical blockade of IL-1 may benefit patients with BRAF wild-type tumors and potentially synergize with immunotherapeutic interventions.
Journal ArticleDOI

Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

Julie A. Ellerhorst, +10 more
- 15 Jan 2011 - 
TL;DR: Distinct clinical phenotypes exist for melanomas bearing NRAS and BRAF mutations, whether considered together or separately, and are associated with features known to predict aggressive tumor behavior, most evident at earlier stages of disease progression.
Journal ArticleDOI

Intratumoral Injection of INGN 241, a Nonreplicating Adenovector Expressing the Melanoma-Differentiation Associated Gene-7 (mda-7/IL24): Biologic Outcome in Advanced Cancer Patients

Alex W. Tong, +16 more
- 01 Jan 2005 - 
TL;DR: Intratumoral delivery of INGN 241 induced apoptosis in a large volume of tumor and elicited tumor-regulatory and immune-activating events that are consistent with the preclinical features of MDA-7/IL-24.